[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"immunonutrition\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:immunonutrition":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,83,107],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100518184","oral-supplementation-of-glutamine-on-gastric-cancer-patients-after-gastrectomy-100518184",false,"NCT06027242","Oral Supplementation of Glutamine on Gastric Cancer Patients After Gastrectomy","Inclusion Criteria:\n\n* adult gastric cancer receiving gastrectomy\n\nExclusion Criteria:\n\n* Hepatic insufficiency\n* Renal insufficiency\n* can not tolerate oral or enteral feeding 7 days after gastrectomy\n* can not receive computed tomograph\n* can not waer the wearable devices","ALL","20 Years",{"count":18,"type":19},120,"ESTIMATED","INTERVENTIONAL",[22],"NA","Glutamine has the potentials of immunomodulation and adjustment of protein metabolism. The primary objective of this study is to evaluate the efficacy of glutamine on sarcopenia in gastric adenocarcinoma patients undergoing gastrectomy. The secondary endpoints, including the physical activity, weight loss, and nutritional profiles, will be evaluated among these patients.",[25,26,27],"Gastric Cancer","Immunonutrition","Gastrostomy",[29,30,31],"Gastric cancer","Gastrectomy","sarcopenia","RECRUITING","2025-12-16",{"date":35,"type":36},"2025-12-23","ACTUAL",{"date":38,"type":36},"2023-02-21",{"date":40,"type":19},"2026-08-30",{"name":42,"class":43},"National Taiwan University Hospital","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":20,"phases":58,"briefSummary":59,"conditions":60,"keywords":71,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":44},"100609100","pre-habilitation-within-eras-protocol-for-gynecologic-oncology-surgery-the-preeras-study-100609100","NCT07210164","Pre-habilitation Within ERAS Protocol for Gynecologic Oncology Surgery: The Pre_ERAS Study","Prehabilitation With Exercise and Immunonutrition (Ocoxin®) in the Perioperative Management of Gynecologic Malignancies Under ERAS Protocol.","Pre_ERAS","Inclusion Criteria:\n\n* Type of gynecological malignancy: endometrial cancer, ovarian cancer, cervical cancer, treated with laparotomy after the decision of the gynecological-oncology unit (positive opinion of the Multidisciplinary Tumor Board - MDT)\n* Patient age: 18 to 85 years\n* General condition of the patient: ASA score I-III\n* Consent to implement the accelerated recovery protocol - Enhanced recovery after surgery (ERAS)\n* Sufficient understanding of the Greek language\n* Provision of signed, after thorough information, consent to participate in the study\n\nExclusion Criteria:\n\n* Women with performance status: ECOG \\>2 and ASA score \\>III\n* Women who have not been informed and have given written consent","FEMALE","18 Years","85 Years",{"count":57,"type":19},100,[22],"ERAS (Enhanced Recovery After Surgery) protocols are step-by-step care plans that help patients recover faster after surgery. They focus on keeping the body's normal functions, lowering stress from surgery, and supporting a quicker recovery. In gynecologic cancer surgeries, ERAS has been shown to help patients do better, have fewer problems, and leave the hospital sooner.\n\nA prehabilitation program, in combination with ERAS protocols, aims to optimize patients' physical and psychological condition prior to surgery for gynecological cancers. Interventions may include tailored exercise, nutritional support, respiratory training, and psychological preparation. By enhancing baseline fitness and resilience, prehabilitation improves the body's ability to tolerate surgical stress, reduces complications, and facilitates a faster, smoother recovery within the ERAS framework.",[61,62,63,64,26,65,66,67,68,69,70],"ERAS","Compliance","Quality of Life (QOL)","Excercise","Post Operative Pain","Laparotomy Patients","Surgical Complication","Gynaecological Malignancies","Gynaecologic Cancer","Gynaecological Oncology",[72,61,73,26],"Prehabilitation","Gynecologic Cancers","2025-09-29",{"date":76,"type":36},"2025-10-07",{"date":78,"type":19},"2025-12-01",{"date":80,"type":19},"2029-12-30",{"name":82,"class":43},"Aristotle University Of Thessaloniki",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":15,"minAge":54,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":20,"phases":92,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":106},"100572700","oral-immunonutrition-therapy-to-reduce-acute-toxicity-after-neoadjuvant-chemoradiotherapy-pancreatic-cancer-patients-100572700","NCT06736678","Oral Immunonutrition Therapy to Reduce Acute Toxicity After Neoadjuvant Chemoradiotherapy Pancreatic Cancer Patients","Efficacy of Oral Immunonutrition Therapy in Reducing Acute Toxicity After Neoadjuvant Chemoradiotherapy Among Pancreatic Cancer Patients: a Prospective, Single-arm Clinical Trial","Inclusion Criteria:\n\n* 1\\. Pathologically confirmed pancreatic ductal epithelial malignant tumors;\n* 2\\. Resectable pancreatic cancer treated with neoadjuvant chemoradiotherapy, or nonresectable locally advanced pancreatic cancer treated with neoadjuvant or radical chemoradiotherapy;\n* 3.Nutritional Risk Screening 2002 (NRS2002) ≥3 and Patient-Generated Subjective Global Assessment (PG-SGA) performance status B;\n* 4\\. Age 18 years and older;\n* 5\\. Eastern Cooperative Oncology Group (ECOG) performance status 0-1;\n* 6\\. Expected survival time more than 3 months;\n* 7\\. History of antineoplastic therapy;\n\nExclusion Criteria:\n\n* 1\\. Known allergy or intolerance to any component of investigational Oral Immunonutrition;\n* 2\\. History of Oral Immunonutrition use within one month prior to enrollment;\n* 3\\. Tumor compresses the major duodenal papilla, and \u002For appeared jaundice, acute pancreatitis;\n* 4\\. Patients with contraindications for antineoplastic therapy, such as coronary heart disease, cerebral infarction, cerebral hemorrhage or other serious diseases;\n* 5\\. Liver, kidney and blood coagulation function failure;\n* 6\\. Patients with hemopathy;\n* 7\\. Patients with active infections;\n* 8\\. Patients with other primary tumor;\n* 9\\. Patients with other medical diseases that seriously affected nutritional status;\n* 10.Subjects deemed by the investigator have other factors that may be ineligible for enrollment;",{"count":91,"type":19},98,[22],"A prospective, single-arm clinical trial is conducted to investigate the role of oral immunonutrion in reducing acute toxicity after neoadjuvant chemoradiotherapy among pancreatic cancer patients.",[95,96,26],"Pancreatic Cancer","Neoadjuvant Chemoradiotherapy","2024-12-12",{"date":99,"type":36},"2024-12-17",{"date":101,"type":36},"2024-08-26",{"date":103,"type":19},"2025-09-30",{"name":105,"class":43},"Sun Yat-sen University",2,{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":15,"minAge":54,"maxAge":55,"enrollmentInfo":114,"targetDuration":4,"studyType":116,"phases":4,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":44},"100503310","whole-course-immunonutrition-combined-with-chemoradiotherapyicis-for-local-advanced-patients-with-inoperable-esophageal-squamous-cell-carcinoma-100503310","NCT05833594","Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs for Local Advanced Patients With Inoperable Esophageal Squamous Cell Carcinoma","Anhui Provincial Hospita","Inclusion Criteria:\n\n* 18-85 years old;\n* Eastern Cooperative Oncology Group (ECOG) 0-2;\n* Esophageal squamous cell carcinoma;\n* cT2-4aN0-3M0 (AJCC 8th) confirmed by radiological examination;\n* initial unresectable at initial diagnosis confirmed by thoracic surgeons;\n* Treatment naive;\n* No contraindications for adjuvant chemoradiotherapy;\n* Signature of inform consent.\n\nExclusion Criteria:\n\n* younger than 18 years old or older than 85 years old;\n* ECOG\\>2;\n* Esophageal adenocarcinoma, small-cell cancer and other pathological types;\n* cT1anyNM0, cT4banyNM0, c anyTanyNM0 confirmed by radiological examination;\n* Resectable at initial diagnosis confirmed by thoracic surgeons;\n* Previous treatment of chemotherapy, radiotherapy, and other treatment;\n* Contraindications for chemoradiotherapy;\n* No signature of inform consent.",{"count":115,"type":19},70,"OBSERVATIONAL","Chemoradiotherapy has been a standard modality for inoperable locally advance esophageal carcinoma. The goal of this randomized control study is to compare the feasibility, and survival benefits of whole-course immunonutrition combined with chemoradiotherapy±ICIs for local advanced patients with inoperable esophageal squamous cell carcinoma. The main questions it aims to answer are: • If the feasibility and safety of whole-course immunonutrition combined with chemoradiotherapy±ICIs is better. • If the survival benefits (1, 2 and 3-years progression free survival) of whole-course immunonutrition combined with chemoradiotherapy±ICIs is longer. The Experimental group will receive a combination immunonutrition of omega-3 fatty acids, and glutamine, whereas the control group will receive standard formula.",[119,120,26,121],"Esophageal Squamous Cell Carcinoma","Chemoradiotherapy","Inoperable","2023-12-20",{"date":124,"type":36},"2023-12-26",{"date":126,"type":36},"2023-07-01",{"date":128,"type":19},"2026-12-01",{"name":130,"class":131},"Anhui Provincial Hospital","OTHER_GOV"]